Gene Analysis Shared Resource

遗传流行病学和风险评估（GERA）计划的目标是：1）利用遗传学和分子生物学的巨大进步，以了解人类癌症病因学中的遗传，环境和基因-环境相互作用; 2）利用这些相同的进展，以了解癌症预后和生存的分子流行病学;以及3）开发和应用新的统计和信息学方法，用于遗传和分子流行病学研究的设计和分析。我们的癌症病因学研究采用以家庭为基础的病例对照和队列研究设计，重点关注癌症的遗传流行病学，癌前病变和中间表型，以及非遗传风险因素和描述性流行病学。我们也在研究基于肿瘤表型的病因异质性。我们的癌症预后研究重点是宿主因素，包括遗传和血清生物标志物以及影响预后的生活方式因素;肿瘤生物标志物;和生存率。正在开发新的方法，设计和分析遗传和分子流行病学研究，建立在我们的专业知识，生物统计学，医学信息学和生物信息学。为了实现这些目标，我们组建了一个由来自10多个部门或部门的32名多学科调查人员组成的团队。同行评审的资金总额为881万美元，来自32.6个分配的赠款，其中71%来自国家癌症研究所。自2008年以来，该计划已经产生了622篇出版物，43%反映了计划内的合作，61%反映了计划间的合作。在胰腺、肺、卵巢、乳腺、结肠、淋巴瘤和乳房X线摄影乳腺密度的流行病学，以及统计遗传学和医学及生物信息学文献方面做出了显著贡献。该计划的领导是由帕克提供。该方案广泛使用共用设施。在未来5年，我们将继续在癌症病因学和预后方面的创新研究，重点是基因组学，新技术和方法的开发和应用，以及转化到临床和人群以及回到实验室为生物学提供信息。

The goals of the Genetic Epidemiology and Risk Assessment (GERA) Program are to: 1) Utilize the tremendous advances in genetics and molecular biology in order to understand genetic, environmental, and gene-environment interactions in the etiology of cancer in human populations; 2) Utilize these same advances in order to understand the molecular epidemiology of cancer prognosis and survivorship; and 3) Develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. Our cancer etiology studies use family-based, case-control and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as non-genetic risk factors and descriptive epidemiology. We are also addressing etiologic heterogeneity based on tumor phenotype. Our cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis; tumor biomarkers; and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics and bioinformatics. To achieve these goals we have assembled a team of 32 multidisciplinary investigators from over 10 divisions or departments. Total peer-reviewed funding is $8.81 M from 32.6 assigned grants, with 71% coming from the National Cancer Institute. Since 2008, the program has generated 622 publications, 43% reflecting intra-programmatic collaborations and 61% reflecting inter-programmatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, lymphoma, and mammographic breast density, as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan and Parker. The program makes extensive use of shared facilities. In the next 5 years, we will continue our innovative research in cancer etiology and prognosis with a focus on genomics, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.